New molecular entity NDAs up in FY 2004
Executive Summary
The number of new molecular entity submissions to FDA increased slightly in fiscal year 2004. FDA received 28 NME submissions in FY 2004 (ended Sept. 30), up from 25 NMEs in FY 2003 and 22 the prior year. NME submissions still have not climbed back to the level of three to five years ago. The agency received 32 NMEs in FY 2001, 30 in 2000 and 37 in 1999. BLA submissions spiked in 2004 with 20 new applications, up from eight in 2003. Nine BLAs were submitted in 2002 and eight in 2001...
You may also be interested in...
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.
Merck’s Winrevair Well Positioned To Benefit From Medicare Part D Redesign
Significant cost sharing reductions under the redesign will enhance uptake of the pulmonary arterial hypertension drug. The trade-off is a 20% mandatory price discount in the catastrophic phase.